Boceprevir

A User's Guide

Paul Y. Kwo, Rong Zhao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Given its essential role in the process of hepatitis C virus (HCV) replication, the viral NS3/4A serine protease is arguably the most thoroughly characterized HCV enzyme and the most intensively pursued anti-HCV target for drug development thus far. Recent data have demonstrated promise for the NS3 protease inhibitor boceprevir, which, when added to the standard of care peginterferon and ribavirin, improves sustained virological response while shortening duration of therapy in genotype-1-infected individuals. This review discusses the mechanism of action of boceprevir, its effects on HCV, and its viral resistance.

Original languageEnglish
Pages (from-to)537-553
Number of pages17
JournalClinics in Liver Disease
Volume15
Issue number3
DOIs
StatePublished - Aug 2011

Fingerprint

Hepacivirus
Ribavirin
Serine Proteases
Standard of Care
Virus Replication
Protease Inhibitors
Genotype
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
Enzymes
Pharmaceutical Preparations
Therapeutics

Keywords

  • Boceprevir
  • Direct-acting antiviral
  • Hepatitis C virus
  • Protease inhibitor
  • Resistance

ASJC Scopus subject areas

  • Hepatology

Cite this

Boceprevir : A User's Guide. / Kwo, Paul Y.; Zhao, Rong.

In: Clinics in Liver Disease, Vol. 15, No. 3, 08.2011, p. 537-553.

Research output: Contribution to journalArticle

Kwo, Paul Y. ; Zhao, Rong. / Boceprevir : A User's Guide. In: Clinics in Liver Disease. 2011 ; Vol. 15, No. 3. pp. 537-553.
@article{d1cac0358d344003b1aab70f18312d67,
title = "Boceprevir: A User's Guide",
abstract = "Given its essential role in the process of hepatitis C virus (HCV) replication, the viral NS3/4A serine protease is arguably the most thoroughly characterized HCV enzyme and the most intensively pursued anti-HCV target for drug development thus far. Recent data have demonstrated promise for the NS3 protease inhibitor boceprevir, which, when added to the standard of care peginterferon and ribavirin, improves sustained virological response while shortening duration of therapy in genotype-1-infected individuals. This review discusses the mechanism of action of boceprevir, its effects on HCV, and its viral resistance.",
keywords = "Boceprevir, Direct-acting antiviral, Hepatitis C virus, Protease inhibitor, Resistance",
author = "Kwo, {Paul Y.} and Rong Zhao",
year = "2011",
month = "8",
doi = "10.1016/j.cld.2011.05.005",
language = "English",
volume = "15",
pages = "537--553",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Boceprevir

T2 - A User's Guide

AU - Kwo, Paul Y.

AU - Zhao, Rong

PY - 2011/8

Y1 - 2011/8

N2 - Given its essential role in the process of hepatitis C virus (HCV) replication, the viral NS3/4A serine protease is arguably the most thoroughly characterized HCV enzyme and the most intensively pursued anti-HCV target for drug development thus far. Recent data have demonstrated promise for the NS3 protease inhibitor boceprevir, which, when added to the standard of care peginterferon and ribavirin, improves sustained virological response while shortening duration of therapy in genotype-1-infected individuals. This review discusses the mechanism of action of boceprevir, its effects on HCV, and its viral resistance.

AB - Given its essential role in the process of hepatitis C virus (HCV) replication, the viral NS3/4A serine protease is arguably the most thoroughly characterized HCV enzyme and the most intensively pursued anti-HCV target for drug development thus far. Recent data have demonstrated promise for the NS3 protease inhibitor boceprevir, which, when added to the standard of care peginterferon and ribavirin, improves sustained virological response while shortening duration of therapy in genotype-1-infected individuals. This review discusses the mechanism of action of boceprevir, its effects on HCV, and its viral resistance.

KW - Boceprevir

KW - Direct-acting antiviral

KW - Hepatitis C virus

KW - Protease inhibitor

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=80051951128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051951128&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2011.05.005

DO - 10.1016/j.cld.2011.05.005

M3 - Article

VL - 15

SP - 537

EP - 553

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -